NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

北美的到轉染市場-至2028年的產業趨勢與預測

North America Transfection Market - Industry Trends and Forecast to 2028

出版商 Data Bridge Market Research Private Limited 商品編碼 977685
出版日期 內容資訊 英文 100 Pages
商品交期: 3-5個工作天內
價格
北美的到轉染市場-至2028年的產業趨勢與預測 North America Transfection Market - Industry Trends and Forecast to 2028
出版日期: 2020年11月01日內容資訊: 英文 100 Pages
簡介

北美的轉染的市場規模,預計從2021年到2028年的預測期間9.4%的年複合成長率擴大。為這個新的市場報告,與2018年的成果,從作為基準年的2020年至2027年的預測資料包含著2019年。

本報告提供北美的轉染市場相關調查,市場概要,以及各類型,各方法,各產品,各分子類型,各用途,各階段,各終端用戶,各國的趨勢,及加入此市場的主要企業簡介等資訊

目錄

第1章 簡介

第2章 市場區隔

第3章 摘要整理

第4章 重要考察

  • 市場整體趨勢
    • 各方法/模式
    • 各終端用戶
    • 各用途
    • 各階段
  • 生物醫藥品的初期及後期階段的細胞株開發及基因治療的病毒載體生產
    • 用中國倉鼠卵巢(CHO)細胞生產的已通過核准抗體清單及哺乳類的表現媒介使用的可選擇的標記清單

第5章 法律規範

  • 歐洲聯盟的法規方案
  • 美國的法規方案
  • 日本的法規方案
  • 中國的法規方案

第6章 市場概要

  • 促進因素
    • 慢性疾病的盛行率上升
    • 合成生物學產品的開發
    • 嵌合遺傳基因的需求高漲
    • 臨床研究所使用的大規模轉染
    • 蛋白質的產生的生物醫藥品的使用
  • 阻礙因素
    • 轉染產品的成本高
    • 轉染試劑的選擇中有效性
    • 轉染程序引起的細胞損傷
  • 市場機會
    • 新興市場開拓
    • 市場參與者的策略性舉措
    • 政府的輔助增加
    • 投資等級劇增
  • 課題
    • 長期批審
    • 缺乏病毒相關轉染用安全等級的實驗室
    • 受訓練的專家不足

第7章 COVID-19醫療保健產業中COVID-19對北美的轉染市場的影響

  • 概要
  • 對價格的影響
  • 對需求的影響
  • 對供應鏈的影響
  • 製造商的策略性舉措
  • 結論

第8章 北美的轉染市場,各類型

  • 概要
  • 一時性轉染
    • 各階段
    • 各產品
  • 穩定性轉染
    • 各階段
    • 各產品

第9章 北美的轉染市場,各方法

  • 概要
  • 非病毒性方法
    • 化學性
    • 物理性
  • 病毒法
    • 反轉錄病毒轉染
    • 腺病毒轉染
    • 慢病毒轉染
    • 其他

第10章 北美的轉染市場,各方法

  • 概要
  • 非病毒性的方法
    • 化學性
    • 物理性
  • 病毒法
    • 反轉錄病毒轉染
    • 腺病毒轉染
    • 慢病毒轉染
    • 其他

第11章 北美的轉染市場,各產品

  • 概要
  • 試劑和套件
    • 陽離子性脂質
    • 陽離子聚合物
    • 奈米粒子
    • 套件
    • CUVETTE CHAMBER
    • 其他
  • 計量儀器
    • 電穿孔系統
    • 電力細胞融合發電機
    • 動電學的轉染系統
    • HEPTA系統
    • 管材準備站
    • RT-PCR
    • 槍系統
    • 微量盤式分析儀
    • Sonoporation系統
    • 顯微鏡
    • 其他

第12章 北美的轉染市場,各生物

  • 概要
  • 哺乳類細胞
  • 植物
  • 真菌
  • 病毒
  • 細菌

第13章 北美的轉染市場,各分子類型

  • 概要
  • 質體DNA
  • 低分子干涉RNA(SIRNA)
  • 蛋白質
  • DNA寡核苷酸
  • 核糖核蛋白質複合體(RNPS)
  • 其他

第14章 北美的轉染市場,各用途

  • 概要
  • 各類型
    • in vitro
    • in vivo
    • 生物生產
    • 其他
  • 各業界
    • 合成生物學
    • 農業
    • 其他

第15章 北美的轉染市場,各階段

  • 概要
  • 研究
  • 前臨床
  • 臨床階段
  • 商用

第16章 北美的轉染市場,各終端用戶

  • 概要
  • 生物醫藥品
  • 醫藥品研究開發受託機關(CROS)
  • 醫藥品研究開發、受託製造廠商(CMOS/CDMOS)
  • 學術機構
  • 醫院
  • 臨床實驗室
  • 其他

第17章 北美的轉染市場,各流通管道

  • 概要
  • 直接競標
  • 零售
  • 其他

第18章 北美的轉染市場,各地區

  • 北美
  • 美國
  • 加拿大
  • 墨西哥

第19章 全球 MARKET轉染:企業形勢

  • 企業佔有率分析:北美

第20章 SWOT分析

第21章 企業簡介

  • THERMOFISHER SCIENTIFIC INC.
  • ROCHE MOLECULAR SYSTEMS, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)
  • QIAGEN
  • PROMEGA CORPORATION
  • TAKARA BIO INC.
  • BIO-RAD LABORATORIES, INC.
  • LONZA
  • CYTIVA
  • ALTOGEN BIOSYSTEMS
  • AMYRIS
  • APPLIED BIOLOGICAL MATERIALS INC. (ABM)
  • AUTOLUS
  • AVANTI POLAR LIPIDS (A SUBSIDIARY OF CRODA INTERNATIONAL PLC)
  • BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER)
  • CODEXIS
  • CONAGEN, INC.
  • FUJIFILM IRVINE SCIENTIFIC (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION)
  • GENLANTIS INC.
  • GENO TECHNOLOGY INC., USA
  • GINKGO BIOWORKS
  • IMPOSSIBLE FOODS INC.
  • MAXCYTE, INC.
  • MERCK KGAA
  • MIRUS BIO LLC.
  • ORIGENE TECHNOLOGIES, INC.
  • PERKINELMER CHEMAGEN TECHNOLOGIE GMBH (A SUBSIDIARY OF PERKINELMER INC.)
  • POLYPLUS TRANSFECTION
  • POSEIDA THERAPEUTICS, INC.
  • R&D SYSTEMS, INC.
  • SBS GENETECH
  • SIGNAGEN LABORATORIES
  • TWIST BIOSCIENCE
  • VERVE THERAPEUTICS, INC.
  • ZYMERGEN INC.

第22章 問卷調查

第23章 相關報告

目錄

North America transfection market is projected to register a CAGR of 9.4% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.

Market Segmentation:

North America Transfection Market, By Type (Transient Transfection, Stable Transfection), Methods (Non-Viral Methods, Viral Methods), CRISPR Transfection Methods (Non-Viral Methods, Viral Methods), Products (Reagent & Kits, Instrument, Software), Organism (Mammalian Cells, Plants, Fungi, Virus, Bacteria), Types of Molecule (Plasmid DNA, Small Interfering RNA (siRNA), Proteins, DNA Oligonucleotides, Ribonucleoprotein Complexes (RNPs), Others), Application (In Vitro Application, In Vivo Application, Bioproduction, Others), Stage (Research, Preclinical, Clinical Phases, Commercial), End User (Biopharma, Contract Research Organizations (CROs), Contract Manufacturing Organization/ Contract Development and Manufacturing Organization (CMOs/CDMOs), Academia, Hospitals, Clinical Labs, Others), Distribution Channel (Direct Tender, Retail Sales, Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2028.

Some of the major factors contributing to the growth of North America transfection market are:

  • Increasing occurrences of chronic diseases
  • Utilization of biopharmaceuticals in the production of proteins

Market Players:

The key market players for North America transfection market are listed below:

  • Mirus Bio LLC.
  • Promega Corporation
  • Bio-Rad Laboratories, Inc.
  • Merck KGaA
  • Lonza
  • MaxCyte, Inc.
  • Altogen Biosystems
  • SBS Genetech
  • FUJIFILM Irvine Scientific (A Subsidiary of FUJIFILM Holdings Corporation)
  • Avanti Polar Lipids (A Subsidiary of Croda International Plc)
  • Cytiva
  • Geno Technology Inc.
  • R&D Systems, Inc.
  • Takara Bio Inc.
  • Thermofisher Scientific Inc.
  • QIAGEN
  • OriGene Technologies, Inc.
  • Applied Biological Materials Inc. (abm)
  • Beckman Coulter, Inc. (A Subsidiary of Danaher)
  • Amyris
  • Codexis
  • SignaGen Laboratories
  • Impossible Foods Inc.
  • Genlantis Inc.
  • Zymergen Inc.
  • Ginkgo Bioworks
  • Verve Therapeutics, Inc.
  • Conagen, Inc.
  • Poseida Therapeutics, Inc.
  • Twist Bioscience

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF NORTH AMERICA TRANSFECTION MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 TRANSIENT TRANSFECTION OF TRANSFECTION LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 MARKET APPLICATION COVERAGE GRID
  • 2.11 VENDOR SHARE ANALYSIS
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

  • 4.1 TOTAL ADDRESSABLE MARKET
    • 4.1.1 BY METHOD/MODALITY
    • 4.1.2 BY END USER
    • 4.1.3 BY APPLICATION
    • 4.1.4 BY STAGE
  • 4.2 EARLY AND LATE STAGE CELL LINE DEVELOPMENT FOR BIOPHARMA AND VIRAL VECTOR PRODUCTION FOR GENE THERAPY
    • 4.2.1 THE LIST OF APPROVED ANTIBODIES PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS AND LIST OF SELECTABLE MARKERS USED IN MAMMALIAN EXPRESSION VECTORS

5 REGULATORY FRAMEWORK

  • 5.1 EUROPEAN UNION REGULATORY SCENARIO
  • 5.2 U.S. REGULATORY SCENARIO
  • 5.3 JAPAN REGULATORY SCENARIO
  • 5.4 CHINA REGULATORY SCENARIO

6 MARKET OVERVIEW

  • 6.1 DRIVERS
    • 6.1.1 RISE IN THE PREVALENCE OF CHRONIC DISEASES
    • 6.1.2 DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS
    • 6.1.3 GROWING DEMAND OF CHIMERIC GENES
    • 6.1.4 LARGE-SCALE TRANSFECTIONS USED IN CLINICAL RESEARCH
    • 6.1.5 UTILIZATION OF BIOPHARMACEUTICALS IN THE PRODUCTION OF PROTEINS
  • 6.2 RESTRAINTS
    • 6.2.1 HIGH COST OF TRANSFECTION PRODUCTS
    • 6.2.2 SELECTIVE EFFECTIVENESS OF TRANSFECTION REAGENTS
    • 6.2.3 CELL DAMAGE INDUCED BY TRANSFECTION PROCEDURE
  • 6.3 OPPORTUNITIES
    • 6.3.1 EXPLORATION OF EMERGING MARKET
    • 6.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
    • 6.3.3 INCREASING GOVERNMENT SUPPORT
    • 6.3.4 SURGING LEVEL OF INVESTMENT
  • 6.4 CHALLENGES
    • 6.4.1 LONG APPROVAL PROCEDURE
    • 6.4.2 LACK OF SAFETY LEVEL LAB FOR VIRUS ASSOCIATED TRANSFECTION
    • 6.4.3 LACK OF TRAINED PROFESSIONALS

7 COVID-19 IMPACT OF NORTH AMERICA TRANSFECTION MARKET IN HEALTHCARE INDUSTRY

  • 7.1 OVERVIEW
  • 7.2 IMPACT ON THE PRICE
  • 7.3 IMPACT ON DEMAND
  • 7.4 IMPACT ON SUPPLY CHAIN
  • 7.5 STRATEGIC INITIATIVE BY MANUFACTURERS
  • 7.6 CONCLUSION

8 NORTH AMERICA TRANSFECTION MARKET, BY TYPE

  • 8.1 OVERVIEW
  • 8.2 TRANSIENT TRANSFECTION
    • 8.2.1 BY STAGE
      • 8.2.1.1 RESEARCH
      • 8.2.1.2 PRECLINICAL
      • 8.2.1.3 CLINICAL PHASES
      • 8.2.1.4 COMMERCIAL
    • 8.2.2 BY PRODUCT
      • 8.2.2.1 REAGENT & KITS
      • 8.2.2.2 INSTRUMENTS
      • 8.2.2.3 SOFTWARE
  • 8.3 STABLE TRANSECTION
    • 8.3.1 BY STAGE
      • 8.3.1.1 RESEARCH
      • 8.3.1.2 PRECLINICAL
      • 8.3.1.3 CLINICAL PHASES
      • 8.3.1.4 COMMERCIAL
    • 8.3.2 BY PRODUCT
      • 8.3.2.1 REAGENT & KITS
      • 8.3.2.2 INSTRUMENTS
      • 8.3.2.3 SOFTWARE

9 NORTH AMERICA TRANSFECTION MARKET, BY METHODS

  • 9.1 2.1 OVERVIEW
  • 9.2 NON- VIRAL METHODS
    • 9.2.1 CHEMICAL
      • 9.2.1.1 Lipofection Method
      • 9.2.1.2 Calcium Phosphate Precipitation Method
      • 9.2.1.3 Polyethylenimine (PEI)-DNA Condensation Method
      • 9.2.1.4 Others
    • 9.2.2 PHYSICAL
      • 9.2.2.1 Electroporation
      • 9.2.2.2 Direct Microinjection
      • 9.2.2.3 Biolistic Particle Delivery/ Particle Bombardment
      • 9.2.2.4 Magnetofection
      • 9.2.2.5 Sonoporation
      • 9.2.2.6 Others
  • 9.3 VIRAL METHODS
    • 9.3.1 RETROVIRUS TRANSFECTION
    • 9.3.2 ADENOVIRUS TRANSFECTION
    • 9.3.3 LENTIVIRUS TRANSFECTION
    • 9.3.4 OTHERS

10 NORTH AMERICA TRANSFECTION MARKET, BY METHODS

  • 10.1 OVERVIEW
  • 10.2 NON- VIRAL METHODS
    • 10.2.1 CHEMICAL
      • 10.2.1.1 Lipofection Method
      • 10.2.1.2 Calcium Phosphate Precipitation Method
      • 10.2.1.3 Polyethylenimine (PEI)-DNA Condensation Method
      • 10.2.1.4 Others
    • 10.2.2 PHYSICAL
      • 10.2.2.1 Electroporation
      • 10.2.2.2 Direct Microinjection
      • 10.2.2.3 Biolistic Particle Delivery/ Particle Bombardment
      • 10.2.2.4 Magnetofection
      • 10.2.2.5 Sonoporation
      • 10.2.2.6 Others
  • 10.3 VIRAL METHODS
    • 10.3.1 RETROVIRUS TRANSFECTION
    • 10.3.2 ADENOVIRUS TRANSFECTION
    • 10.3.3 LENTIVIRUS TRANSFECTION
    • 10.3.4 OTHERS

11 NORTH AMERICA TRANSFECTION MARKET, BY PRODUCTS

  • 11.1 OVERVIEW
  • 11.2 REAGENTS & KITS
    • 11.2.1 CATIONIC LIPIDS
      • 11.2.1.1 Liposomal Reagents
        • 11.2.1.1.1 L-Dioleoyl Phosphatidylethanolamine (DOPE)
        • 11.2.1.1.2 DOTAP [1,2-Dioleoyloxy-3-Trimethylammonium Propane]
        • 11.2.1.1.3 DOTMA [N-[1(2,3-Dioleoyloxy)Propyl]-N,N,N-Trimethylammonium Chloride]
        • 11.2.1.1.4 Others
      • 11.2.1.2 Non-Liposomal Reagents
        • 11.2.1.2.1 DNA Transfection Reagent
        • 11.2.1.2.2 siRNA Transfection Reagent
        • 11.2.1.2.3 Others
    • 11.2.2 CATIONIC POLYMER
      • 11.2.2.1 DEAE-Dextran
      • 11.2.2.2 Polybrene
      • 11.2.2.3 Polyethyleneimine
      • 11.2.2.4 Dendrimers
      • 11.2.2.5 Others
    • 11.2.3 NANOPARTICLES
      • 11.2.3.1 Systemic Intravenous Injection
      • 11.2.3.2 Direct Intratumoral Injection
    • 11.2.4 KITS
      • 11.2.4.1 Transporter Transfection Reagent
      • 11.2.4.2 GMP Transfection Reagent
      • 11.2.4.3 Neon Electroporation
      • 11.2.4.4 Cellfectin Ii Transfection Reagent
      • 11.2.4.5 DMRIE-C Transfection Reagent
      • 11.2.4.6 Lipofectamine Transfection Reagent
      • 11.2.4.7 Lipofectin Transfection Reagent
      • 11.2.4.8 Oligofectamine Transfection Reagent
      • 11.2.4.9 Optifect Transfection Reagent
      • 11.2.4.10 Cell Specific Transfection Reagent
      • 11.2.4.11 Gene Gun Kit
      • 11.2.4.12 Plasmid Transfection Reagent
      • 11.2.4.13 Others
    • 11.2.5 CUVETTE CHAMBER
    • 11.2.6 OTHERS
  • 11.3 INSTRUMENT
    • 11.3.1 ELECTROPORATION SYSTEM
      • 11.3.1.1 Neon Transfection System
      • 11.3.1.2 Others
    • 11.3.2 ELECTRO-CELL FUSION GENERATOR
    • 11.3.3 ELECTRO-KINETIC TRANSFECTION SYSTEM
    • 11.3.4 HEPTA SYSTEM
    • 11.3.5 TUBING PREP STATION
    • 11.3.6 RT-PCR
    • 11.3.7 GUN SYSTEM
    • 11.3.8 MICROPLATE READER
    • 11.3.9 SONOPORATION SYSTEM
    • 11.3.10 MICROSCOPES
    • 11.3.11 OTHERS

12 NORTH AMERICA TRANSFECTION MARKET, BY ORGANISM

  • 12.1 OVERVIEW
  • 12.2 MAMMALIAN CELLS
  • 12.3 PLANTS
  • 12.4 FUNGI
  • 12.5 VIRUS
  • 12.6 BACTERIA

13 NORTH AMERICA TRANSFECTION MARKET, BY TYPES OF MOLECULE

  • 13.1 OVERVIEW
  • 13.2 PLASMID DNA
  • 13.3 SMALL INTERFERING RNA (SIRNA)
  • 13.4 PROTEINS
  • 13.5 DNA OLIGONUCLEOTIDES
  • 13.6 RIBONUCLEOPROTEIN COMPLEXES (RNPS)
  • 13.7 OTHERS

14 NORTH AMERICA TRANSFECTION MARKET, BY APPLICATION

  • 14.1 OVERVIEW
  • 14.2 BY TYPE
    • 14.2.1 IN VITRO APPLICATION
      • 14.2.1.1 Gene Expression
      • 14.2.1.2 RNA Interference
    • 14.2.2 IN VIVO APPLICATION
      • 14.2.2.1 Gene Therapy
      • 14.2.2.2 Cellular-Based Therapy
    • 14.2.3 BIOPRODUCTION
      • 14.2.3.1 Antibody/Protein Production
      • 14.2.3.2 Virus Production
    • 14.2.4 OTHERS
  • 14.3 BY INDUSTRY
    • 14.3.1 SYNTHETIC BIOLOGY
      • 14.3.1.1 Biopharma
      • 14.3.1.2 Monoclonal Antibodies (mAbs)
      • 14.3.1.3 Recombinant Proteins
      • 14.3.1.4 Biofuels
      • 14.3.1.5 Cell Line Development
      • 14.3.1.6 Flavors & Fragrances
      • 14.3.1.7 Enzyme Engineering & Production
      • 14.3.1.8 Specialty Chemicals
    • 14.3.2 AGRICULTURE
    • 14.3.3 OTHERS

15 NORTH AMERICA TRANSFECTION MARKET, BY STAGES

  • 15.1 OVERVIEW
  • 15.2 RESEARCH
  • 15.3 PRECLINICAL
  • 15.4 CLINICAL PHASES
  • 15.5 COMMERCIAL

16 NORTH AMERICA TRANSFECTION MARKET, BY END USER

  • 16.1 OVERVIEW
  • 16.2 BIOPHARMA
  • 16.3 CONTRACT RESEARCH ORGANIZATIONS (CROS)
  • 16.4 CONTRACT MANUFACTURING ORGANIZATION/ CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CMOS/CDMOS)
  • 16.5 ACADEMIA
  • 16.6 HOSPITALS
  • 16.7 CLINICAL LABS
  • 16.8 OTHERS

17 NORTH AMERICA TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL

  • 17.1 OVERVIEW
  • 17.2 DIRECT TENDERS
  • 17.3 RETAIL SALES
  • 17.4 OTHERS

18 NORTH AMERICA TRASNFECTION MARKET, BY GEOGRAPHY

  • 18.1 NORTH AMERICA
    • 18.1.1 U.S.
    • 18.1.2 CANADA
    • 18.1.3 MEXICO

19 NORTH AMERICA TRANSFECTION MARKET: COMPANY LANDSCAPE

  • 19.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

20 SWOT ANALYSIS

21 COMPANY PROFILE

  • 21.1 THERMOFISHER SCIENTIFIC INC.
    • 21.1.1 COMPANY SNAPSHOT
    • 21.1.2 REVENUE ANALYSIS
    • 21.1.3 COMPANY SHARE ANALYSIS
    • 21.1.4 PRODUCT PORTFOLIO
    • 21.1.5 RECENT DEVELOPMENTS
  • 21.2 ROCHE MOLECULAR SYSTEMS, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)
    • 21.2.1 COMPANY SNAPSHOT
    • 21.2.2 REVENUE ANALYSIS
    • 21.2.3 COMAPYN SHARE ANALYSIS
    • 21.2.4 PRODUCT PORTFOLIO
    • 21.2.5 RECENT DEVELOPMENTS
  • 21.3 QIAGEN
    • 21.3.1 COMPANY SNAPSHOT
    • 21.3.2 REVENUE ANALYSIS
    • 21.3.3 COMPANY SHARE ANALYSIS
    • 21.3.4 PRODUCT PORTFOLIO
    • 21.3.5 RECENT DEVELOPMENTS
  • 21.4 PROMEGA CORPORATION
    • 21.4.1 COMPANY SNAPSHOT
    • 21.4.2 COMPANY SHARE ANALYSIS
    • 21.4.3 PRODUCT PORTFOLIO
    • 21.4.4 RECENT DEVELOPMENTS
  • 21.5 TAKARA BIO INC.
    • 21.5.1 COMPANY SNAPSHOT
    • 21.5.2 REVENUE ANALYSIS
    • 21.5.3 COMPANY SHARE ANALYSIS
    • 21.5.4 PRODUCT PORTFOLIO
    • 21.5.5 RECENT DEVELOPMENTS
  • 21.6 BIO-RAD LABORATORIES, INC.
    • 21.6.1 COMPANY SNAPSHOT
    • 21.6.2 REVENUE ANANLYSIS
    • 21.6.3 PRODUCT PORTFOLIO
    • 21.6.4 RECENT DEVELOPMENT
  • 21.7 LONZA
    • 21.7.1 COMPANY SNAPSHOT
    • 21.7.2 REVENUE ANANLYSIS
    • 21.7.3 PRODUCT PORTFOLIO
    • 21.7.4 RECENT DEVELOPMENTS
  • 21.8 CYTIVA
    • 21.8.1 COMPANY SNAPSHOT
    • 21.8.2 PRODUCT PORTFOLIO
    • 21.8.3 RECENT DEVELOPMENTS
  • 21.9 ALTOGEN BIOSYSTEMS
    • 21.9.1 COMPANY SNAPSHOT
    • 21.9.2 PRODUCT PORTFOLIO
    • 21.9.3 RECENT DEVELOPMENTS
  • 21.10 AMYRIS
    • 21.10.1 COMPANY SNAPSHOT
    • 21.10.2 REVENUE ANALYSIS
    • 21.10.3 PRODUCT PORTFOLIO
    • 21.10.4 RECENT DEVELOPMENTS
  • 21.11 APPLIED BIOLOGICAL MATERIALS INC. (ABM)
    • 21.11.1 COMPANY SNAPSHOT
    • 21.11.2 PRODUCT PORTFOLIO
    • 21.11.3 RECENT DEVELOPMENT
  • 21.12 AUTOLUS
    • 21.12.1 COMPANY SNAPSHOT
    • 21.12.2 PRODUCT PORTFOLIO
    • 21.12.3 RECENT DEVELOPMENTS
  • 21.13 AVANTI POLAR LIPIDS (A SUBSIDIARY OF CRODA INTERNATIONAL PLC)
    • 21.13.1 COMPANY SNAPSHOT
    • 21.13.2 REVENUE ANALYSIS
    • 21.13.3 PRODUCT PORTFOLIO
    • 21.13.4 RECENT DEVELOPMENT
  • 21.14 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER)
    • 21.14.1 COMPANY SNAPSHOT
    • 21.14.2 REVENUE ANALYSIS
    • 21.14.3 PRODUCT PORTFOLIO
    • 21.14.4 RECENT DEVELOPMENTS
  • 21.15 CODEXIS
    • 21.15.1 COMPANY SNAPSHOT
    • 21.15.2 REVENUE ANALYSIS
    • 21.15.3 PRODUCT PORTFOLIO
    • 21.15.4 RECENT DEVELOPMENTS
  • 21.16 CONAGEN, INC.
    • 21.16.1 COMPANY SNAPSHOT
    • 21.16.2 PRODUCT PORTFOLIO
    • 21.16.3 RECENT DEVELOPMENTS
  • 21.17 FUJIFILM IRVINE SCIENTIFIC (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION)
    • 21.17.1 COMPANY SNAPSHOT
    • 21.17.2 REVENUE ANANLYSIS
    • 21.17.3 PRODUCT PORTFOLIO
    • 21.17.4 RECENT DEVELOPMENT
  • 21.18 GENLANTIS INC.
    • 21.18.1 COMPANY SNAPSHOT
    • 21.18.2 PRODUCT PORTFOLIO
    • 21.18.3 RECENT DEVELOPMENTS
  • 21.19 GENO TECHNOLOGY INC., USA
    • 21.19.1 COMPANY SNAPSHOT
    • 21.19.2 PRODUCT PORTFOLIO
    • 21.19.3 RECENT DEVELOPMENTS
  • 21.20 GINKGO BIOWORKS
    • 21.20.1 COMPANY SNAPSHOT
    • 21.20.2 PRODUCT PORTFOLIO
    • 21.20.3 RECENT DEVELOPMENTS
  • 21.21 IMPOSSIBLE FOODS INC.
    • 21.21.1 COMPANY SNAPSHOT
    • 21.21.2 PRODUCT PORTFOLIO
    • 21.21.3 RECENT DEVELOPMENTS
  • 21.22 MAXCYTE, INC.
    • 21.22.1 COMPANY SNAPSHOT
    • 21.22.2 REVENUE ANALYSIS
    • 21.22.3 PRODUCT PORTFOLIO
    • 21.22.4 RECENT DEVELOPMENTS
  • 21.23 MERCK KGAA
    • 21.23.1 COMPANY SNAPSHOT
    • 21.23.2 REVENUE ANALYSIS
    • 21.23.3 PRODUCT PORTFOLIO
    • 21.23.4 RECENT DEVELOPMENTS
  • 21.24 MIRUS BIO LLC.
    • 21.24.1 COMPANY SNAPSHOT
    • 21.24.2 PRODUCT PORTFOLIO
    • 21.24.3 RECENT DEVELOPMENTS
  • 21.25 ORIGENE TECHNOLOGIES, INC.
    • 21.25.1 COMPANY SNAPSHOT
    • 21.25.2 PRODUCT PORTFOLIO
    • 21.25.3 RECENT DEVELOPMENTS
  • 21.26 PERKINELMER CHEMAGEN TECHNOLOGIE GMBH (A SUBSIDIARY OF PERKINELMER INC.)
    • 21.26.1 COMPANY SNAPSHOT
    • 21.26.2 REVENUE ANANLYSIS
    • 21.26.3 PRODUCT PORTFOLIO
    • 21.26.4 RECENT DEVELOPMENTS
  • 21.27 POLYPLUS TRANSFECTION
    • 21.27.1 COMPANY SNAPSHOT
    • 21.27.2 PRODUCT PORTFOLIO
    • 21.27.3 RECENT DEVELOPMENTS
  • 21.28 POSEIDA THERAPEUTICS, INC.
    • 21.28.1 COMPANY SNAPSHOT
    • 21.28.2 PRODUCT PORTFOLIO
    • 21.28.3 RECENT DEVELOPMENTS
  • 21.29 R&D SYSTEMS, INC.
    • 21.29.1 COMPANY SNAPSHOT
    • 21.29.2 PRODUCT PORTFOLIO
    • 21.29.3 RECENT DEVELOPMENT
  • 21.30 SBS GENETECH
    • 21.30.1 COMPANY SNAPSHOT
    • 21.30.2 PRODUCT PORTFOLIO
    • 21.30.3 RECENT DEVELOPMENTS
  • 21.31 SIGNAGEN LABORATORIES
    • 21.31.1 COMPANY SNAPSHOT
    • 21.31.2 PRODUCT PORTFOLIO
    • 21.31.3 RECENT DEVELOPMENTS
  • 21.32 TWIST BIOSCIENCE
    • 21.32.1 COMPANY SNAPSHOT
    • 21.32.2 REVENUE ANALYSIS
    • 21.32.3 PRODUCT PORTFOLIO
    • 21.32.4 RECENT DEVELOPMENTS
  • 21.33 VERVE THERAPEUTICS, INC.
    • 21.33.1 COMPANY SNAPSHOT
    • 21.33.2 PRODUCT PORTFOLIO
    • 21.33.3 RECENT DEVELOPMENTS
  • 21.34 ZYMERGEN INC.
    • 21.34.1 COMPANY SNAPSHOT
    • 21.34.2 PRODUCT PORTFOLIO
    • 21.34.3 RECENT DEVELOPMENTS

22 QUESTIONNAIRE

23 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 LIST OF APPROVED ANTIBODIES PRODUCED IN CHO CELLS
  • TABLE 2 EU DIRECTIVES AND REGULATIONS RELATED TO CLINICAL TRIALS INVOLVING GTMPS
  • TABLE 3 GOVERNMENT ENTITIES THAT ARE IN CHARGE OF TYPE 2 USES
  • TABLE 4 NORTH AMERICA TRANSFECTION MARK

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA TRANSFECTION MARKET: SEGMENTATION
  • FIGURE 2 NORTH AMERICA TRANSFECTION MARKET : DATA TRIANGULATION
  • FIGURE 3 NORTH AMERICA TRANSFECTION MARKET: DROC ANALYSIS
  • FIGURE 4 NORTH AMERICA TRANSFECTION MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
  • FIGURE 5 NORTH AMERICA TRANSFECTION MARKET: COMPANY RESEARCH ANALYSIS
  • FIGURE 6 NORTH AMERICA TRANSFECTION MARKET: MULTIVARIATE MODELLING
  • FIGURE 7 NORTH AMERICA TRANSFECTION MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 8 NORTH AMERICA TRANSFECTION MARKET: DBMR MARKET POSITION GRID
  • FIGURE 9 NORTH AMERICA TRANSFECTION MARKET: MARKET APPLICATION COVERAGE GRID
  • FIGURE 10 NORTH AMERICA TRANSFECTION MARKET: VENDOR SHARE ANALYSIS
  • FIGURE 11 NORTH AMERICA TRANSFECTION MARKET: SEGMENTATION
  • FIGURE 12 INCREASING OCCURENCE OF CHRONIC DISEASES AND DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS IS DRIVING THE NORTH AMERICA TRANSFECTION MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
  • FIGURE 13 TRANSIENT TRANSFECTION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA TRANSFECTION MARKET IN 2021 & 2028
  • FIGURE 14 APPROVAL PROCESS FOR GENE THERAPY IN CHINA
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA TRANSFECTION MARKET
  • FIGURE 16 NORTH AMERICA TRANSFECTION MARKET: BY TYPE, 2020
  • FIGURE 17 NORTH AMERICA TRANSFECTION MARKET: BY TYPE, 2020-2028 (USD MILLION)
  • FIGURE 18 NORTH AMERICA TRANSFECTION MARKET: BY TYPE, CAGR (2021-2028)
  • FIGURE 19 NORTH AMERICA TRANSFECTION MARKET: BY TYPE, LIFELINE CURVE
  • FIGURE 20 NORTH AMERICA TRANSFECTION MARKET: BY METHODS, 2020
  • FIGURE 21 NORTH AMERICA TRANSFECTION MARKET: BY METHODS, 2020-2028 (USD MILLION)
  • FIGURE 22 NORTH AMERICA TRANSFECTION MARKET: BY METHODS, CAGR (2021-2028)
  • FIGURE 23 NORTH AMERICA TRANSFECTION MARKET: BY METHODS, LIFELINE CURVE
  • FIGURE 24 NORTH AMERICA TRANSFECTION MARKET: BY METHODS, 2020
  • FIGURE 25 NORTH AMERICA TRANSFECTION MARKET: BY METHODS, 2020-2028 (USD MILLION)
  • FIGURE 26 NORTH AMERICA TRANSFECTION MARKET: BY METHODS, CAGR (2021-2028)
  • FIGURE 27 NORTH AMERICA TRANSFECTION MARKET: BY METHODS, LIFELINE CURVE
  • FIGURE 28 NORTH AMERICA TRANSFECTION MARKET: BY PRODUCT, 2020
  • FIGURE 29 NORTH AMERICA TRANSFECTION MARKET: BY PRODUCT, 2020-2028 (USD MILLION)
  • FIGURE 30 NORTH AMERICA TRANSFECTION MARKET: BY PRODUCT, CAGR (2021-2028)
  • FIGURE 31 NORTH AMERICA TRANSFECTION MARKET: BY PRODUCT, LIFELINE CURVE
  • FIGURE 32 NORTH AMERICA TRANSFECTION MARKET: BY ORGANISM, 2020
  • FIGURE 33 NORTH AMERICA TRANSFECTION MARKET: BY ORGANISM, 2020-2028 (USD MILLION)
  • FIGURE 34 NORTH AMERICA TRANSFECTION MARKET: BY ORGANISM, CAGR (2021-2028)
  • FIGURE 35 NORTH AMERICA TRANSFECTION MARKET: BY ORGANISM, LIFELINE CURVE
  • FIGURE 36 NORTH AMERICA TRANSFECTION MARKET: BY TYPES OF MOLECULE, 2020
  • FIGURE 37 NORTH AMERICA TRANSFECTION MARKET: BY TYPES OF MOLECULE, 2020-2028 (USD MILLION)
  • FIGURE 38 NORTH AMERICA TRANSFECTION MARKET: BY TYPES OF MOLECULE, CAGR (2021-2028)
  • FIGURE 39 NORTH AMERICA TRANSFECTION MARKET: BY TYPES OF MOLECULE LIFELINE CURVE
  • FIGURE 40 NORTH AMERICA TRANSFECTION MARKET: BY APPLICATION, 2020
  • FIGURE 41 NORTH AMERICA TRANSFECTION MARKET: BY APPLICATION, 2020-2028 (USD MILLION)
  • FIGURE 42 NORTH AMERICA TRANSFECTION MARKET: BY APPLICATION, CAGR (2021-2028)
  • FIGURE 43 NORTH AMERICA TRANSFECTION MARKET: BY APPLICATION, LIFELINE CURVE
  • FIGURE 44 NORTH AMERICA TRANSFECTION MARKET: BY STAGES, 2020
  • FIGURE 45 NORTH AMERICA TRANSFECTION MARKET: BY STAGES, 2020-2028 (USD MILLION)
  • FIGURE 46 NORTH AMERICA TRANSFECTION MARKET: BY STAGES, CAGR (2021-2028)
  • FIGURE 47 NORTH AMERICA TRANSFECTION MARKET: BY STAGES, LIFELINE CURVE
  • FIGURE 48 NORTH AMERICA TRANSFECTION MARKET: BY END USER, 2020
  • FIGURE 49 NORTH AMERICA TRANSFECTION MARKET: BY END USER, 2020-2028 (USD MILLION)
  • FIGURE 50 NORTH AMERICA TRANSFECTION MARKET: BY END USER, CAGR (2021-2028)
  • FIGURE 51 NORTH AMERICA TRANSFECTION MARKET: BY END USER, LIFELINE CURVE
  • FIGURE 52 NORTH AMERICA TRANSFECTION MARKET: BY DISTRIBUTION CHANNEL, 2020
  • FIGURE 53 NORTH AMERICA TRANSFECTION MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
  • FIGURE 54 NORTH AMERICA TRANSFECTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
  • FIGURE 55 NORTH AMERICA TRANSFECTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE